Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers by Ota, T et al.
Treatment of squamous cell carcinoma of the uterine cervix with
radiation therapy alone: long-term survival, late complications, and
incidence of second cancers
T Ota*,1, N Takeshima
1, T Tabata
1, K Hasumi
1 and K Takizawa
1
1Department of Gynecology, Cancer Institute Hospital, Ariake 3-10-6, Koutou-ku, Tokyo 135-8550, Japan
The objective of this retrospective study was to determine the survival rate, incidence of late complications, and incidence of second
cancers when radiation therapy alone is used for carcinoma of the uterine cervix. Between 1971 and 1995, 1495 patients with
squamous cell carcinoma of the uterine cervix (stages I–IV) were treated with radiation therapy alone in our hospital. Radiation
therapy consisted of a combination of high-dose-rate intracavitary brachytherapy and external beam radiotherapy. The cumulative
5-year survival rates for stages Ib, II, and III/IVa carcinoma were 93.5, 77.0, and 60.3%, respectively, and the 10-year survival rates were
90.9, 74.5, and 56.1%, respectively. Local control rates for stages Ib, II, and III/IVa carcinoma were 92.0, 79.4 and 64.2%, respectively.
Eighty-two (5.5%) patients suffered grade III/IV or V (fatal) complications. A second cancer developed in 13 (0.87%) patients. Second
cancers were observed most frequently in the rectum (five cases), colon (three cases), and uterine body (two cases). Long-term
follow-up data revealed that our method of radiation therapy alone for locally advanced carcinoma of the uterine cervix is effective,
with low incidences of late complications and second cancers.
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Cervical cancer is one of the most common cancers in women
worldwide. Despite worldwide efforts at screening with the aim of
detecting cervical cancer in the early stage, many cancers are not
discovered until already advanced. Traditionally, radical hysterec-
tomy or radiation therapy alone has been accepted as standard
treatment for early-stage invasive cervical cancer, and locally
advanced cancer has been treated by radiotherapy alone consisting
of a combination of high-dose-rate intracavitary brachytherapy
(ICBT) and external beam radiotherapy (EBRT) (Coia et al, 1990;
Komaki et al, 1995; Barillot et al, 1997). In the past few years,
substantial advances in the management of locally advanced
cervical cancer have been reported. Five randomised trials showed
improved survival and local control when cisplatin-based chemo-
therapy was added concurrently to radiation treatment in patients
with locally advanced cervical cancer (Keys et al, 1999; Morris
et al, 1999; Rose et al, 1999; Whitney et al, 1999; Peters et al, 2000).
This combined modality approach produced an absolute increase
in 5-year survival of 12% as compared with radiation therapy
alone and resulted in a sudden change in the standard of care for
this disease. Now that concurrent treatment with cisplatin-based
chemotherapy and radiotherapy is the standard treatment for
locally advanced cervical cancer, the main issue in treatment is
how chemotherapy is used, not much attention is given to the
radiotherapy method.
For more than 30 years, we have treated locally advanced
cervical cancer by radiation therapy alone. In this study, we
retrospectively analysed 1495 cases of cervical carcinoma treated
at our institution from 1971 to 1995 by a unique combination
EBRT/ICBT regimen. We were interested in determining the long-
term survival rate as well as the incidences of late complications
and second cancers.
METHODS
Study population
From 1971 through 1995, a total of 1600 new patients with primary
invasive cervical carcinoma were treated by radiotherapy alone at
the Cancer Institute Hospital, Tokyo, Japan. Of these patients, 1495
(93.4%) had pure squamous cell carcinoma (SCC). The remaining
105 patients with non-SCC were excluded from this study. After
an initial clinical examination, all patients underwent a complete
staging workup, including a complete blood count, blood chemistry
tests, chest radiography, and biopsy of the cervical tumour. Cysto-
scopy and drip infusion pyelography were performed in all
patients; only in suspicious case was sigmoidoscopy performed.
The numbers of patients are shown by cancer stages in
Table 1. Stages were determined according to the International
Federation of Gynecology and Obstetrics criteria. Patients with
distant metastasis (ie stage IVb cervical carcinoma) before
treatment and patients treated by chemotherapy before radiation
were excluded.
Treatment schedule
The radiation treatment schedule is shown in Figure 1. A
combination of EBRT and ICBT was used in all patients according
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sto a regimen that is unique to our institution. For all patients,
including those with stage III or IV disease, it was planned that
EBRT and ICBT would begin simultaneously. However, in 431
patients (28.9%) we were unable to insert the uterine applicator at
the time of radiotherapy was initiated because of the tumour bulk,
thus, EBRT was started alone without the use of a midline shield
until 20Gy was delivered; ICBT was performed later. In patients
who initially received 20Gy with unshielded EBRT, reduction of
one to three fractions of ICBT was considered, depending on the
radiation effect. Occasionally, ICBT could not be applied even after
EBRT. Indeed, in 13 patients, radiotherapy was achieved with
EBRT alone. Overall treatment time ranged from 6 to 7 weeks.
External beam radiotherapy to a total dose of 50Gy was
delivered in 2Gy fractions per day, 5 days a week, by using an
isocentric technique via a pair of parallel opposed anterior and
posterior ports and 18-MV X-ray beam. Both pelvic and para-
aortic fields were irradiated except in patients with non-bulky
stage I disease; only pelvic radiation was performed in these
patients. The superior margin of the para-aortic radiation field was
the L2–3 intervertebral space, the lateral limit of each pelvic field
was 2cm lateral to the most lateral point of the pelvic wall, and the
lower limit was the caudal pole of the obturator foramen. A
midline shield was inserted throughout the external radiation
period (except in patients in whom EBRT was started before ICBT)
regardless of the stage of cervical carcinoma. The midline shield
was 4cm wide at the central axis.
High-dose-rate remote afterloading ICBT was performed with a
uterine applicator and two vaginal applicators used with
60Co
sources (2–4 Ci). Low-dose consecutive brachytherapy was
prescribed to all patients. A dose of 4Gy in one fraction was
routinely prescribed to point A, which was located 2cm superior to
the cervical ostium and 2cm lateral to the central axis of the
uterus. Intracavitary brachytherapy was performed with two or
three insertions per week, for a total of 10 fractions. When ICBT
was applied to a bulky tumour at the start of treatment, the dose of
radiation delivered to point A was gradually adjusted in parallel
with the reduction in tumour size. Because ICBT was divided into
10 fractions, this process was accomplished without severe
morbidity. Orthogonal radiographs were obtained for each
insertion, and each treatment session was planned. In the majority
of cases, neither anaesthesia nor sedation was necessary during
ICBT. EBRT and ICBT were not performed on the same day. When
ICBT was performed, EBRT was performed the next day.
Survival
Survival of each patient was calculated from the date therapy was
started to the date of the last follow-up examination. Survival
curves were drawn according to the Kaplan–Meier method. The
log-rank test was used for univariate analysis. P-values of less than
0.05 were considered statistically significant.
Complete response was defined as absence of cancer cells as
determined by smear cytology and biopsy of the uterine cervix.
Recurrence was defined as reappearance of cancer cells.
Local control rate
Complete response was defined as no remaining cancer cells
according to cytologic and histologic assessment for over 3 months
after radiotherapy. Local control was defined as absence of
recurrence in the pelvic cavity.
Late complications
Late rectal and bladder complications and non-rectal gastrointest-
inal sequelae (small bowel complications) were graded according
to the Radiation Therapy Oncology Group (RTOG)/the European
Organization for Research and Treatment of Cancer (EORTC)
scoring system (Cox et al, 1995).
Second cancers
Cancer in the radiation field that differed histologically from the
primary cancer, as distinguished from recurrence or metastasis
from the primary tumour, was considered a second cancer. The
person-years proposed by Schoenberg and Myer (1972) was used
for statistical analysis. The disease expectancy table used for the
present study was the one provided by the Center for Cancer
Control and Information Services, National Cancer Center, Japan,
which calculated expected ratios from 1995.
Follow-up
Follow-up examinations were done every 3 months during the first
5 years after treatment and then at 6-month intervals for the next 5
years. All follow-up examinations included pelvic examination
with cytologic assessment of the uterine cervix and tumour marker
SCC antigen, and identification of late complications. Every 6
months, we obtained a computed tomography scan of the
abdomen and a chest X-ray firm. All patients were followed up
for more than 10 years after radiation therapy. Our hospital is one
of a few institutions that are permitted to access the family registry
database. We consulted the district legal affairs bureau for survival
information or the cause of the death pertaining to each patient, so
our records were complete; no patient was lost to follow-up. Of the
total 1495 patients, 1224 (81.9%) were followed up directly at the
hospital and 271 (18.1%) were followed up indirectly through the
district legal affairs bureau.
RESULTS
Study population
Patient numbers by cancer stage of the study are shown in Table 1.
Mean age of the patients was 60.6 years (range, 29–93 years). Of
the total 1495 patients, the numbers of patients with stage Ib, II,
and III/IVa disease were 174 (11.6), 608 (40.7), and 713 (47.7%),
respectively.
Table 1 Cervical carcinomas treated with radiotherapy alone
Clinical stage No. patients %
Stage Ib 174 11.6
Stage IIa 25 1.7
40.7 Stage IIb 583 39.0
Stage IIIa 16 1.1 45.1
Stage IIIb 658 44.0
Stage IVa 39 2.6
Total 1495 100
g
g
ICBT
EBRT
4 Gy×10=40 Gy (3–4 weeks)
2 Gy×25=50 Gy (6–7 weeks)
Figure 1 Treatment schedule for radiation therapy.
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Disease-specific survival curves are shown according to cancer
stages in Figure 2. The cumulative 5-year survival rates for stages
Ib, II, and III/IVa disease were 93.5, 77.0, and 60.3%, respectively.
Ten-year survival rates for stages Ib, II, and III/IVa disease were
90.9, 74.5, and 56.1%, respectively.
Local control
Local control and recurrence are shown in Figure 3. Of the total
1495 patients, 1430 patients had a complete response, as shown
by cytologic and histologic assessment. Of these 1430 patients,
472 patients suffered recurrence (local recurrence, 329 patients;
distant metastasis, 143 patients). Thus, the local control rate was
73.6%. Local control rates for stages Ib, II, and III/IVa disease
were 92.0, 79.4, and 64.2%, respectively. The most common sites
of recurrence were the lung (55 patients) and supraclavicular
lymph nodes (35 patients).
Late complications
Late complications are presented in Table 2. According to the
RTOG/EORTC scoring system, grade III, IV, or V (fatal) late com-
plications involving the rectum, small bowel, or urinary tract were
observed in 97 (6.5%) cases. Sixty-one cases (4.1%) involved stage
III disease. The crude incidences of grade III, IV, and V (fatal)
rectal complications were 1.1% (17 patients), 1.5% (22 patients),
and 0.07% (1 patient), respectively. One patient with a rectal
complication died of uncontrolled rectal bleeding 8 years after
radiation therapy. The crude incidences of grade III and IV small
bowel complications were 0% (0 patients) and 0.7% (10 patients),
respectively. The crude incidences of grade III and IV urinary tract
complications were 1.5% (23 patients) and 0.8% (12 patients),
respectively. The most common grade III complications were
haematuria (1.5%) and proctitis (1.1%). The most common grade
IV complications were rectovaginal fistula (1.1%) and vesico-
vaginal fistula (0.8%). Nine patients (0.6%; one with stage I
disease, two with stage II disease, five with stage III disease, and
one with stage IV disease) required reconstruction of both the
urinary tract and lower gastrointestinal tract.
Second cancers
The incidence of second cancers and observed/expected ratio of
incident cancers are shown in Table 3. Second cancers were
observed in 13 cases (0.87%). The most frequent sites were the
rectum (five cases), colon (three cases), and uterine body (two
cases). Analysis on a site-by-site basis revealed an excess of second
cancers in the rectum and uterine body and of occurrences of acute
leukaemia.
DISCUSSION
Our radiation therapy regimen differs from the international
standard. The concept is unique in that the primary tumour is
treated by intracavitary irradiation, and the pelvic and para-aortic
lymph nodes are treated by external beam irradiation to a total
50Gy in 25 fractions. Intracavitary brachytherapy, at a dose of 4Gy
in one fraction routinely prescribed to point A, was performed
with two or three insertions per week, for a total of 10 fractions
in total. It is essential that both radiation therapies are started
simultaneously and that EBRT is performed with a midline shield,
no matter what the disease stage. It is difficult to insert the uterine
applicator into a bulky tumour at the beginning of treatment. Skill
is needed. A midline shield was used throughout the external
radiation period, so it is possible that dose of radiation delivered to
point A was higher. The other important factor is that the overall
treatment time is 7 weeks or less.
Our regimen yielded good results and decreased the incidence of
complications for a number of reasons. First, the overall treatment
period is short. Several studies have shown that overall treatment
time is a significant prognostic factor for patients with cervical
cancer treated with radiation therapy alone (Fyles et al, 1992;
Girinsky et al, 1993; Lanciano et al, 1993; Perez et al, 1995;
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Figure 2 Disease-specific survival per clinical stage for patients with
cervical carcinoma treated with radiotherapy alone.
Control rate: (958+143)/1495=73.6%
Total
1495
Persistent
65
CR
1430
Recurrence (–)
958
Recurrence (+)
472
Local
329
Distant
143
Figure 3 Local control of cervical carcinoma treated by radiotherapy
alone.
Table 2 Grades of late complications according to site
Grade III Grade IV Grade V (fatal)
Rectum 13 (0.9%) 21 (1.4%) 1 (0.07%)
Small bowel 11 (0.7%) — —
Bladder 17 (1.1%) 9 (0.6%) —
Combined — 10 (0.7%) —
Total 41 (2.7%) 40 (2.7%) 1 (0.07%)
Total 82 cases (5.5%).
Table 3 Second cancers after treatment with radiotherapy alone
Site Observed Expected O/E
Rectum 5 1.9 2.6
Colon 3 3.3 0.9
Uterine body 2 0.7 2.9
Ovary 1 1.0 1.0
Acute leukaemia 1 0.5 1.9
Pelvic MFH 1 — —
Abbreviation: MFH¼malignant fibrous histiocytoma.
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sDelaloye et al, 1996). Fyles et al (1992) reported the influence of
treatment duration on local control. Using three statistical
methods of analysis in 830 patients, they observed loss of
local control of approximately 1% per day when treatment lasted
over 30 days, most evident in stage III and IV patients. Girinsky
et al (1993) also reported decreased rates of local control
and survival when the treatment period was longer than 52 days.
By multiple regression analysis, they observed loss of 1.1%
local control per day when the treatment period was prolonged
from 52 days to more than 62 days. All patients in the current
study received radiation therapy within 7 weeks, and this yielded
a better result. Second, ICBT is divided into many fractions.
According to the linear quadratic model, tumour cells sustain
more damage than normal cells by a reduction in the exposure
dose and fractionation. The cure rate is improved by controlling
normal tissue side effects, easing late complications, and main-
taining equal doses of radiation. Intracavitary brachytherapy is
more difficult than EBRT, but greater efficacy and fewer
complications result (Barendsen, 1982; Fowler, 1989; Brenner
and Hall, 1992; Dale and Jones, 1998).
Perez et al (1999) investigated correlation between irradiation
therapy and sequelae. They graded sequelae as follows: grade 2,
producing major symptoms, repeated occurrences requiring short-
term (less than 4 weeks) hospitalisation for diagnosis and non-
surgical management; grade 3, requiring an operative procedure
for correction or prolonged hospitalisation (over 4 weeks) or life
threatening. For disease stages II or more, they reported grade 2
morbidity of 10–12% and grade 3 morbidity of 10%. The most
frequent grade 2 sequelae were cystitis and proctitis (0.7–3%), and
the most common grade 3 sequelae were vesicovaginal fistula
(0.6–2%), rectovaginal fistula (0.8–3%), and intestinal obstruction
(0.8–4%). Nakano et al (2005) also reported late toxicity of
radiation therapy. The 10-year actuarial grade 3–5 complication
rate was 4.4% in the rectosigmoid colon, 0.9% in the bladder, and
3.3% in the small intestine. Considering these data, morbidity after
radiotherapy in our patient population was acceptable. However,
survival data of a considerable proportion of the study patients
were obtained from the family register database. We believe the
survival data are accurate. However, radiotherapy-related mor-
bidity might have been underestimated.
An important issue in the treatment of cervical cancer is how to
treat advanced-stage disease, which affects the majority of patients.
The reported survival of patients with stage III cervical cancer
treated with radiation therapy alone is between 30 and 50%
(Barillot et al, 1997). Perez et al (1999) reported 1456 patients
given EBRT (whole pelvis and central shielding, total 50–60Gy,
depending on tumour size) and ICBT (80–90Gy at point A for
stage IIb–IV disease). The 10-year survival rate was 65% for
patients with stage IIb disease and 40% for patients with stage III
disease, but there were no long-term survivors among patients
with stage IV disease. Logsdon and Eifel (1999) reported 983
patients with stage IIIb SCC treated with various radiotherapies,
including EBRT and ICBT. The overall survival was 32%. Barillot
et al (1997) reported a large multi-centre study of 1875 patients
treated with radiation alone. Specific survival at 5 years was 70%
for stage IIb, 55% for stage IIIa, 45% for stage IIIb, and 10% for
stage IV disease. Nakano et al (2005) also reported long-term
follow-up data for 1148 patients treated with EBRT (whole pelvis
and central shielding, total 45–50Gy at 1.8–2Gy per fraction) and
ICBT (24Gy in four fractions). The 5- and 10-year cause-specific
survival rates were 80 and 74%, respectively, for stage II disease
and 66 and 59%, respectively, for stage III disease.
Radiation therapy is known to cause various malignancies,
including leukaemia, sarcoma, thyroid carcinoma, and lung
carcinoma. Boice et al (1985) examined data from 15 cancer
registries in eight countries and compared the number of second
cancers reported for 182040 women against the number expected
had the same risk prevailed as in the general population. They
found an increased risk for cancers of the bladder, rectum, vagina,
and caecum. Arai et al (1991) reported significantly higher
incidences of second cancers in the rectum, bladder, and lung as
well as leukaemia. Kleinerman et al (1995) described a large-scale
study of 49828 patients with cervical cancer treated with radiation
therapy and 16713 matched patients treated without radiotherapy.
They reported that most of the second cancers were of the rectum,
vagina, vulva, and bladder, and they concluded that radiation is an
important cause of the second cancers, with no evidence that the
risk returns to a normal level. Second cancers were observed in 13
of our patients (0.87%), most frequently in the rectum (five cases),
colon (three cases), and uterine body (two cases). Although there
are many reports on radiation-induced cancer, such cancers
occurred in less than 1% of our patients. Although our radio-
therapy regimen causes some complications, the benefits of the
treatment outweigh the disadvantages. Continued improvement in
radiotherapeutic techniques, along with diagnosis at younger ages
and earlier stages, will result in longer survival times for patients.
This may in turn increase the significance of radiation-related
second cancers.
In recent years, several groups have reported concurrent chemo-
radiation to improve the survival of patients with locally advanced
cervical carcinoma (Keys et al, 1999; Morris et al, 1999; Rose et al,
1999; Whitney et al, 1999; Peters et al, 2000). Cisplatin is the most
active cytotoxic agent against cervical cancer. Questions pertaining
to treatment of cervical cancer are focused mainly on chemother-
apy regimens, so there is a tendency to ignore the radiotherapy
method.
In 1999, the National Cancer Institute (USA) published an
announcement stating that cisplatin-based chemotherapy should
be used concomitantly with radiation therapy in cases of cervical
cancer. However, there were not an adequate numbers of patients
with advanced cancer in the studies published, particularly
patients with pelvic and/or para-aortic lymph node metastasis.
We know from surgical series that the incidence of positive para-
aortic nodes is less than 10% for stage II, 20% for stage II, 30%
for stage III, and 40% for stage IV disease (Berman et al, 1984).
Although the current study is a retrospective one, it involved
a purely consecutive series of patients regardless of pelvic and/or
para-aortic lymph node status before treatment, so the data may be
of great value.
In conclusion, long-term results of our ICBT/EBRT regimen
for cervical cancer are reviewed herein. Our method of irradiation
is unique, but it provides a good result and a decreased incidence
of complications. Our study is one of only a few long-term follow-
up studies involving a large number of patients, and it yielded
valuable data pertaining to the incidence of second cancers follow-
ing radiation therapy for cervical cancer. The standard treatment
for locally advanced cervical cancer is gradually changing to
concurrent chemoradiation. The main issue in the treatment of
cervical cancer is how chemotherapy is used, but we believe the
radiation methodology needs further discussion.
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